Cemiplimab Monotherapy for First-line Treatment of Advanced Non-small-cell Lung Cancer with PD-L1 of at Least 50%: A Multicentre, Open-label, Global, Phase 3, Randomised, Controlled Trial
Sezer, Ahmet; Kilickap, Saadettin; Gümüş, Mahmut; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Turk, Haci M; Cicin, Irfan; Bentsion, Dmitry; Gladkov, Oleg; Clingan, Philip; Sriuranpong, Virote; Rizvi, Naiyer; Gao, Bo; Li, Siyu; Lee, Sue; McGuire, Kristina; Chen, Chieh-I; Makharadze, Tamta; Paydas, Semra; Nechaeva, Marina; Seebach, Frank; Weinreich, David M; Yancopoulos, George D; Gullo, Giuseppe; Lowy, Israel; Rietschel, Petra
pdfen2021
